Introduction
Background
Myocarditis is collection of diseases of infectious, toxic, and autoimmune etiologies characterized by inflammation of the heart. Subsequent myocardial destruction can lead to dilated cardiomyopathy.
Myocarditis is an elusive illness to study, diagnose, and treat because the clinical presentation may range from nearly asymptomatic to overt heart failure requiring transplantation; a myriad of causes exist, and it is occasionally the unrecognized culprit in cases of sudden death.
Pathophysiology
Myocarditis is defined as inflammatory changes in the heart muscle and is characterized by myocyte necrosis.
Animal models of viral myocarditis have lead to a much greater understanding of the pathophysiology of acute, severe myocarditis and correlate with the findings in susceptible patients who apparently uptake viral RNA and develop a cytotoxic necrosis and rapid (1-2 d) cell death without the appearance of the interstitial infiltrate usually associated with myocarditis.
Over 4-14 days, those cells that survive the initial insult, in response to macrophage activation and cytokine expression, develop the classic, histologically apparent infiltration of mononuclear cells. In this subacute viral-clearing phase, natural killer cells target myocardium expressing viral RNA and continue myocyte necrosis. Tumor necrosis factor is also involved in rapidly clearing virus, but its involvement results in the further recruitment of inflammatory cells, activates endothelial cells, and has negative inotropic effects. In the latter stages of the subacute process, cytotoxic T lymphocytes infiltrate the myocardium and direct lysis of cardiocytes, which present virus fragments via the histocompatibility complex on the surface of myocyte membrane. Neutralizing antiviral antibodies also develop to assist in the clearing of virus.
In the chronic phases, the deleterious effects of either inadequate or inappropriately abundant immune response can lead to the unfortunate long-term sequelae of dilated cardiomyopathy and heart failure. In animal models of insufficient immune response, viral replication can continue and cause chronic destruction of myocytes. Biopsy results of patients with acute myocarditis who develop dilated cardiomyopathy demonstrate changes consistent with those seen in polymerase chain reaction (PCR) amplifying RNA from enteroviruses. On the opposite spectrum of immune activity, overabundant T cells may continue activity into the chronic phase and also may cause tissue destruction and heart failure.
Frequency
United States
The true incidence of myocarditis is unknown because many cases are asymptomatic, and some symptoms related to significant morbidity may not be appropriately credited. One major urban US medical examiners office attributed 1.3% of sudden and unexpected deaths to myocarditis1 , consistent with other autopsy studies that demonstrate evidence of myocardial inflammation in 1-1.5% of deaths. In the United States, viral and medication-related cases are the most commonly identified causes.
International
Internationally other etiologies (ie, Chagas disease, diphtheria) play a greater role than in the United States, and true frequency of disease is even more difficult to appreciate.
Mortality/Morbidity
Because of its difficulty in diagnosis, the large number of cases that likely never come to medical attention, and its previously underappreciated role in sudden dysrhythmic death, morbidity and mortality data are difficult to construct.
- Rarely, acute myocarditis is fulminant and leads rapidly to death.
- Mortality for clinically significant and biopsy proven myocarditis varies widely. Recent studies have demonstrated death to be as low as 4% of cases for patients without heart failure and with no persistent viral genome expression. On the opposite end of the spectrum, in patients with persistent viral genome expression, myocarditis related mortality may be as high as 25%.
- The appropriate delicate balance of the immune response to viral invasion of myocytes indicates that a certain number of individuals, perhaps with genetic predispositions, will advance to dilated cardiomyopathy and heart failure, the most common long-term sequelae in those patients who do not recover completely.
Sex
The male-to-female ratio is 1.5:1.
Age
The average age of patients with myocarditis is 42 years. It is a prominent cause of sudden cardiac death in young adults, accounting for 8-12% of such deaths.
Clinical
History
- Many patients present with a nonspecific illness characterized by fatigue, mild dyspnea, and myalgias. A few patients present acutely with fulminant congestive heart failure (CHF) secondary to widespread myocardial involvement. Small and focal areas of inflammation in electrically sensitive areas may be the etiology in patients whose initial presentation is sudden death.
- Most cases of myocarditis are subclinical; therefore, the patient rarely seeks medical attention during acute illness. These subclinical cases may have transient ECG abnormalities.
- An antecedent viral syndrome is present in more than one half of patients with myocarditis. The appearance of cardiac-specific symptoms occurs primarily in the subacute virus-clearing phase; therefore, patients commonly present 2 weeks after the acute viremia.
- Fever is present in 20% of patients.
- Other symptoms include fatigue, myalgias and arthralgias, and malaise.
- Chest pain
- Chest discomfort is reported in 35% of patients.
- The pain is most commonly described as a pleuritic, sharp, stabbing precordial pain.
- It may be substernal and squeezing and, therefore, difficult to distinguish from that typical of ischemic pain.
- Dyspnea on exertion is common.
- Orthopnea and shortness of breath at rest may be noted if CHF is present.
- Palpitations are common. Syncope in a patient with a presentation consistent with myocarditis should be carefully approached because it may signal high-grade atrioventricular (AV) block or risk for sudden death.
- Pediatric patients, particularly infants, present with nonspecific symptoms, including the following:
- Fever
- Respiratory distress
- Poor feeding or, in cases with CHF, sweating while feeding
- Cyanosis in severe cases
Physical
Physical findings can range from nearly normal examination findings to signs of fulminant CHF.
- Patients with mild cases of myocarditis have a nontoxic appearance and simply may appear to have a viral syndrome.
- Tachypnea and tachycardia are common. Tachycardia is often out of proportion to fever.
- More acutely ill patients have signs of circulatory impairment due to left ventricular failure.
- A widely inflamed heart shows the classic signs of ventricular dysfunction including the following:
- Jugular venous distention
- Bibasilar crackles
- Ascites
- Peripheral edema
- S3 or a summation gallop may be noted with significant biventricular involvement.
- Intensity of S1 may be diminished.
- Cyanosis may occur.
- Hypotension caused by left ventricular dysfunction is uncommon in the acute setting and indicates a poor prognosis when present.
- Murmurs of mitral or tricuspid regurgitation may be present due to ventricular dilation.
- In cases where a dilated cardiomyopathy has developed, signs of peripheral or pulmonary thromboembolism may be found.
- Diffuse inflammation may develop leading to pericardial effusion, without tamponade, and pericardial and pleural friction rub as the inflammatory process involves surrounding structures.
Causes
The causes of myocarditis are numerous and can be roughly divided into infectious, toxic, and immunologic etiologies, with viral etiologies most common in North America.
- Amongst the infectious causes, viral acute myocarditis is by far the most common.
- Identification of the coxsackie-adenovirus receptor protein explains the prevalence of these viruses as a frequent cause. The receptor is the common target of coxsackievirus B of the enterovirus family and serotypes 2 and 5 of the adenovirus family.
- Other viruses implicated in myocarditis include influenza virus, echovirus, herpes simplex virus, varicella-zoster virus, hepatitis, Epstein-Barr virus, and cytomegalovirus. Hepatitis C, in particular, is becoming a major focus of research.
- Human immunodeficiency virus (HIV) deserves special mention because it seems to function differently than other viruses. Although some evidence indicates that HIV directly invades myocytes, HIV genomes can be amplified from patients without histologic signs of inflammation. In addition, in patients who are infected with HIV, T-cell mediated immune suppression increases the risk of contracting myocarditis due to other infectious causes.
- Nonviral infectious causes are numerous and varied. Worldwide the most common bacterial cause is diphtheria, and, in South America, the protozoal Chagas disease is a common entity. Streptococcal and staphylococcal species and Bartonella, Brucella, Leptospira, and Salmonella species can spread to the myocardium as a consequence of severe cases of endocarditis. Borrelia burgdorferi, the spirochete agent in Lyme disease, is also a known cause of myocarditis. Parasitic myocarditis from trypanosomiasis; trichinosis; and, in the immunocompromised host, toxoplasmosis have been identified.
- Toxic myocarditis has a number of etiologies including both medical agents and environmental agents.
- Among the most common drugs that cause hypersensitivity reactions are clozapine, penicillin, ampicillin, hydrochlorothiazide, methyldopa, and sulfonamide drugs. This syndrome is associated with peripheral eosinophilia, fever, and rash in patients who have biopsy findings of an eosinophilic infiltrate of the myocardium.
- Numerous medications (eg, lithium, doxorubicin, cocaine, numerous catecholamines, acetaminophen) may exert a direct cytotoxic effect on the heart. Zidovudine (AZT) has been associated with myocarditis.
- Environmental toxins include lead, arsenic, and carbon monoxide. Cases have been attributed to Chinese sumac.
- Wasp, scorpion, and spider stings
- Radiation therapy may cause a myocarditis with the development of a dilated cardiomyopathy.
- Immunologic etiologies of myocarditis encompass a number of clinical syndromes and include the following:
- Connective tissue disorders such as systemic lupus erythematosus (SLE), rheumatoid arthritis, scleroderma, and dermatomyositis that can often result in a dismal prognosis
- Idiopathic inflammatory and infiltrative disorders such as Kawasaki disease, sarcoidosis, and giant cell arteritis
- Rejection of the post transplant heart may present as inflammatory myocarditis.
More on Myocarditis |
Overview: Myocarditis |
| Differential Diagnoses & Workup: Myocarditis |
| Treatment & Medication: Myocarditis |
| Follow-up: Myocarditis |
| References |
| Next Page » |
References
Diaz FJ, Loewe C, Jackson A. Death caused by myocarditis in Wayne County, Michigan: a 9-year retrospective study. Am J Forensic Med Pathol. Dec 2006;27(4):300-3. [Medline].
Smith SC, Ladenson JH, Mason JW, Jaffe AS. Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. Circulation. Jan 7 1997;95(1):163-8. [Medline].
Laissy JP, Messin B, Varenne O, Iung B, Karila-Cohen D, Schouman-Claeys E, et al. MRI of acute myocarditis: a comprehensive approach based on various imaging sequences. Chest. Nov 2002;122(5):1638-48. [Medline].
Baughman KL. Diagnosis of myocarditis: death of Dallas criteria. Circulation. Jan 31 2006;113(4):593-5. [Medline].
Ardehali H, Kasper EK, Baughman KL. Diagnostic approach to the patient with cardiomyopathy: whom to biopsy. Am Heart J. Jan 2005;149(1):7-12. [Medline].
Brady WJ, Ferguson JD, Ullman EA, Perron AD. Myocarditis: emergency department recognition and management. Emerg Med Clin North Am. Nov 2004;22(4):865-85. [Medline].
Braunwald E, ed. Myocarditis. In: Heart Disease. 6th ed. 2001:1783-1793.
Checchia P, Kulik P. Guidelines for the Treatment of Myocarditis in Infants and Children and Proceedings of the 2005 Pediatric Cardiac Intensive Care Symposium. November 2006.
Chen H, Liu J, Yang M. Corticosteroids for viral myocarditis. Cochrane Database Syst Rev. 2006;(4):CD004471. [Medline].
Ellis CR, Di Salvo T. Myocarditis: basic and clinical aspects. Cardiol Rev. Jul-Aug 2007;15(4):170-7. [Medline].
Fenster BE, Chan FP, Valentine HA, Yang E, McConnell MV, Berry GJ, et al. Images in cardiovascular medicine. Cardiac magnetic resonance imaging for myocarditis: effective use in medical decision making. Circulation. Jun 6 2006;113(22):e842-3. [Medline].
Hia CP, Yip WC, Tai BC, Quek SC. Immunosuppressive therapy in acute myocarditis: an 18 year systematic review. Arch Dis Child. Jun 2004;89(6):580-4. [Medline].
Khabbaz Z, Grinda JM, Fabiani JN. Extracorporeal life support: an effective and noninvasive way to treat acute necrotizing eosinophilic myocarditis. J Thorac Cardiovasc Surg. Apr 2007;133(4):1122-3; author reply 1123-4. [Medline].
Liu PP, Mason JW. Advances in the understanding of myocarditis. Circulation. Aug 28 2001;104(9):1076-82. [Medline].
Magnani JW, Danik HJ, Dec GW Jr, DiSalvo TG. Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors. Am Heart J. Feb 2006;151(2):463-70. [Medline].
Magnani JW, Dec GW. Myocarditis: current trends in diagnosis and treatment. Circulation. Feb 14 2006;113(6):876-90. [Medline].
Martin TN, Groenning BA, Dargie HJ. Clinical vignette. Diagnosing acute myocarditis using cardiac MRI. Eur Heart J. Feb 2006;27(4):468. [Medline].
Martino TA, Petric M, Weingartl H, Bergelson JM, Opavsky MA, Richardson CD, et al. The coxsackie-adenovirus receptor (CAR) is used by reference strains and clinical isolates representing all six serotypes of coxsackievirus group B and by swine vesicular disease virus. Virology. May 25 2000;271(1):99-108. [Medline].
Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med. Aug 3 1995;333(5):269-75. [Medline].
Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. Oct 10 1996;335(15):1107-14. [Medline].
Pisani B, Taylor DO, Mason JW. Inflammatory myocardial diseases and cardiomyopathies. Am J Med. May 1997;102(5):459-69. [Medline].
Si X, Wang Y, Wong J, Zhang J, McManus BM, Luo H. Dysregulation of the ubiquitin-proteasome system by curcumin suppresses coxsackievirus B3 replication. J Virol. Apr 2007;81(7):3142-50. [Medline].
Stevens LW. Diseases of the myocardium. In: Bennett JC, Plum F, eds. Cecil Textbook of Medicine. 20th ed. Philadelphia, Pa: WB Saunders Co; 1996:328-331.
Vallejo J, Mann DL. Antiinflammatory therapy in myocarditis. Curr Opin Cardiol. May 2003;18(3):189-93. [Medline].
Wang JF, Meissner A, Malek S, Chen Y, Ke Q, Zhang J, et al. Propranolol ameliorates and epinephrine exacerbates progression of acute and chronic viral myocarditis. Am J Physiol Heart Circ Physiol. Oct 2005;289(4):H1577-83. [Medline].
Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, Glanowska G, Wilczewski P, Niklewski T, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation. Jul 3 2001;104(1):39-45. [Medline].
Further Reading
Keywords
myocarditis, heart inflammation, dilated cardiomyopathy, inflammatory changes in the heart muscle, myocyte necrosis, viral myocarditis, acute myocarditis, inflammatory myocarditis, Chagas disease, coxsackievirus B, influenza virus, echovirus, herpes simplex virus, varicella-zoster virus, Epstein-Barr virus, cytomegalovirus, hepatitis C, HIV, diphtheria, Bartonella species, Brucella species, Leptospira species, Salmonella species, endocarditis, Borrelia burgdorferi, toxic myocarditis, parasitic myocarditis
Overview: Myocarditis